Overview

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
To learn if OCSCC patients can be safely given methylnaltrexone for 2 weeks before surgery.
Phase:
Phase 4
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Methylnaltrexone